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Table
Parameter BL Change from BL at:
Wk2 Wk3 Wk4 Wk5 Wk7 Wk9 Wk11 Wk13 Mo4 Mo5 Mo6
BK viremia* (log10 c/mL) 6.2 -0.6 -1.4 -1.8 -2.1 -2.4 -2.7 -3.0 -3.0 -3.9 -3.9 -3.3
BK viruria* (log10 c/mL) 8.7 ND ND -0.7 -1.0 -1.1 -1.5 ND -1.9 -2.1 ND ND
Cr (mg/dL) 2.6 +0.5 +0.3 +0.6 +0.5 +1.0 +0.8 +1.1 +1.2 +0.9 +1.0 +1.3
BUN (mg/dL) 39 -2 -3 0 -2 0 -4 -4 -2 +2 -7 -9
GFR (mL/min/1.73m2) 27.1 -5.0 -3.2 -5.8 -5.0 -8.5 -7.2 -9.1 -9.6 -7.9 -8.5 -10.2
ND indicates not determined
* Viracor BKV qPCR assays in plasma (LLOD, 2 log10 c/mL) or urine (LLOD ¼ 2.7 log10 c/mL)
Figure 1.
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[MMF]). He has remained on sirolimus and MMF. At +16 mos
serum creatinine (Cr) was increasing, BKVN was diagnosed
by biopsy and he was enrolled in CMX001-350.
Methods: CMX001 was given orally at 100 mg twice-weekly
for 6 mos (max tx duration under CMX001-350). Pt was
assessed weekly (Wks 2-5), biweekly (Wks 7-13), and
monthly (Mos 4-6).
Results: Baseline (BL) and changes from BL in BK viremia/
viruria, Cr, BUN and estimated glomerular ﬁltration rate
(GFR, MDRD4) are shown below. No drug-related adverse
events (AEs) or serious AEs were reported. The pt continues
on CMX001 under separate EIND provisions and has stable
renal function and no HD.
Conclusions: BKVN may be underdiagnosed in HSCT. In 1 pt
treated with CMX001, the drug was well tolerated and
controlled the BK viremia. After 6 mos therapy, he has stable
renal functionwithout HD. Our data supports a potential role
for CMX001 in the tx of BKVN.
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Dose intensity is important for disease control in alloge-
neic stem cell transplant (AlloSCT). There is no prospective
data to determine the ideal dose for intravenous busulfan to
be used in reduced intensity AlloSCT. We conducted a phase
I/II controlled randomized study to determine the optimal
dosing schedule of intravenous busulfan. Patients with
advanced hematologic malignancies, 75 years with HLA-
compatible donor were eligible. In the phase 1 portion, seven
dose levels were explored. All patients received ﬂudarabine
at 30mg/m2/d for 4 days. Dose level 5 (11.2mg/kg) was
chosen to be tested for phase II cohort. Eighty patients with
a median age of 56 years were enrolled with 40% having
relapsed/refractory disease. Engraftment occurred in 91%
and complete response was documented in 79% patients
after undergoing transplant. At a median follow up of 91
months, no signiﬁcant difference was seen in terms of non-
relapse mortality of 34% for dose level 5 (11.2mg/kg) vs. 23%
for all other dose levels (P ¼ .4). Signiﬁcant improvement in
cumulative incidence of relapse of 43% vs. 68% (P ¼ .02);
relapse-free-survival of 25% vs. 9% (P ¼ .017) and overall-survival of 27% vs. 9% (P ¼ .037) (Figure 1) was demonstrated
with the dose intensiﬁcation of busulfan. We conclude that
optimizing intravenous busulfan dose intensity in the
preparative regimen leads to improvement in PFS and OS of
patients with advanced hematologic malignancies and may
overcome disease associated poor prognostic factors.388
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Background: Several methods are employed to predict the
outcome of patients undergoing allogeneic hematopoietic
cell transplantation (HCT), including patient characteristics
(e.g., age, performance status, concurrent comorbidities),
diagnosis, and disease status. Armand, et al. (Blood
2012;120:905-913) validated a disease risk index using
diagnosis, cytogenetics, and disease status, which predicted
for overall and progression-free survival. To test this disease
risk index in our patient population, we applied it to patients
receiving ﬂudarabine and pharmacokinetically dose-tar-
geted intravenous busulfan myeloablative conditioning fol-
lowed by allogeneic peripheral blood HCT.
Methods:We analyzed a cohort of 322 patients transplanted
between 2004 and 2009 and assigned them to disease (low,
intermediate, and high) and stage (low and high) risk groups
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survival were compared between the overall risk groups
(low, intermediate, high and very high).
Results: Median age (range) was 49.4 (19-73.8) years. 139
(43%) patients received matched sibling grafts, 120 (37%)
frommatched unrelated donors and 63 (20%) from unrelated
one HLA-antigen/allele mismatched donors. AML was the
most common diagnosis (40%); 31% of all patients were in
CR1. HCT-CI scores were 0 (13%), 1-2 (32%) and 3 or greater
(55%). 42% of patients had a Karnofsky performance status of
100%. 89% of patients were targeted to a busulfan AUC of
5300 mM*min. GVHD prophylaxis consisted of tacrolimus
and methotrexate in 77% of patients. Disease risk by CIBMTR
classiﬁcationwas Early 42%, Intermediate 34%, and Advanced
24%. Disease, stage, and overall risk groups, according to the
criteria set forth by Armand, et al. as well as the corre-
sponding overall (OS) and progression free survivals (PFS)
are shown in the table:Table
Disease risk Stage
risk
% of
patients
Overall risk OS @ 3
yrs
PFS @ 3
yrs
Low Low 11% Low 46% 47%
Low High 4% Intermediate 45% 38%
Intermediate Low 45%
Intermediate High 15% High 39% 34%
High Low 18%
High High 7% Very High 33% 29%
P value 0.34 0.08Conclusion: Our outcomes were different in the Low and
Very High risk groups reported by Armand, et al. This may be
accounted for by a different distribution of diseases or stages
within each overall risk category. Variations in other con-
founding factors also likely contribute to the disparate
results. Further analyses of these differences will need to be
done to evaluate the validity of this disease risk index in our
patients.389
The Cure of HIV with Hematopoietic Cell Transplantation
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Hematopoietic cell transplantation (HCT) has produced
the only known cure of HIV infection in a patient. The patient
had AML and HIV infection and was transplanted in 2007
using peripheral blood stem cells from an adult CCR5-
delta32/delta32 donor. The patient, now known as “The
Berlin Patient”, does not require antiretroviral drug therapy
and, in the analysis of peripheral blood cells and numerous
tissue samples, no proviral DNA can be detected. However,
this successful HCT has not been repeated because the
frequency of CCR5-delta32/delta32 is less than 1% in Cauca-
sians and much less in other ethnic groups, and patients in
need of an HCT generally have only a few potential donors.
Moreover, a very close HLA match between donor and
patient is required when an adult donor is used. In marked
contrast, cord blood HCT requires a signiﬁcantly less strin-
gent HLA match between donor and patient making it much
more feasible to ﬁnd an appropriate unit for an HIV infected
patient. We have tested more than 18,000 cord blood
samples from our cord blood bank and collaborating cord
blood banks, and have identiﬁed 121 cryopreserved CCR5-
delta 32/delta32 units that are available for HCT. An adequate
cord blood cell dose need be only 1 x 10(7) TNC/kg ifa combined haploidentical/cord blood transplant is per-
formed. Projections of HLA match rates for an inventory of
300 homozygous units indicates a probability of ﬁnding an
adequately matched cord blood unit with an adequate cell
dose 82.1% of the time for Caucasian adults and for 85.6% for
Caucasian pediatric patients. For adult African-Americans,
Mexican-Americans and Chinese-Americans the potential
HLA match rates are 31.6%, 48.9% and 13.9%, respectively.
Conclusion: Patients who have an indication for an HCT for
a hematologic malignancy or other disorder, and who are
infected with HIV should be considered for transplantation
with a CCR5-delta32/delta32 cord blood unit.390
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Hemorrhagic cystitis (HC) is a serious complication of
hematopoietic stem cell transplant (HSCT) caused by toxic
effects of the conditioning regimen and/or viral reactivation.
Treatment of HC is supportive and most interventions result
in only transient hemostasis. rFVIIa is a potent procoagulant
and is FDA approved for use in patients with Hemophilia.
Intravenous rFVIIa has been used off-label to establish
hemostasis in multiple conditions. Intravenous rFVIIa in
patients with HC has been shown to brieﬂy stop the bleeding.
We successfully used intravesical installation of rFVIIa to stop
bleeding in patients with post-transplant HC. Pediatric
patients with post-transplant HC were treated with intra-
vesical rFVIIa. The bladder was irrigated by normal saline
(NS) until clear outﬂowwas achieved; then rFVIIa (w 50mcg/
kg) was instilled in 50-100 ml of NS and dwelled for 1-2
hours. The intravesical instillation of rFVIIa resulted in
hemostasis, however it took several days for the bleeding to
completely stop. To enhance hemostasis, we instilled 4 gm of
AA in 50-100 ml of NS immediately after the rFVIIa was
drained and dwelled AA for 1-2 hours. The addition of AA
lead to effective hemostasis and development of intravesical
clot. Intravesical instillation and dwelling of rFVIIa followed
by instillation and dwelling of AA safely and effectively stops
HC post HSCT. Based on this experience we are developing
a standardized protocol to treat post-transplant HC in the
early stages of its development.391
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